Fulgent Genetics Announces Full Abstract Publication of FID-007 Combination Therapy in Head and Neck Cancer at ASCO 2026 Fulgent Genetics, a technology-driven life sciences company with established laboratory services and…
Veracyte to Present Landmark OPTIMA and ENZAMET Trial Data at ASCO 2026, Strengthening Evidence for Genomic Testing in Breast and Prostate Cancer Care Veracyte, a leading cancer diagnostics company, has…
AstraZeneca to Showcase Broad Oncology and Rare Disease Pipeline at ASCO 2026 with Late-Breaking Data Across Liver, Breast, Bladder Cancers and Amyloidosis AstraZeneca will present a comprehensive slate of late-breaking…
Enhertu® Recommended for EU Approval by CHMP for Treatment of Previously Treated HER2-Positive Metastatic Solid Tumors Enhertu® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), has received a positive recommendation…
ClearNote Health to Present New Multi-Cohort Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting ClearNote Health, a company focused on advancing early detection technologies for some…
Virta Health Provides Update on Security Incident and Ongoing Efforts to Protect Personal Information Virta Health Corp. and Virta Medical PC (collectively referred to as “Virta Health”), a leader in…
Baszucki Group Funds Groundbreaking Oxford University Trial Exploring Ketogenic Therapy for Early Psychosis Prevention Baszucki Group has awarded a £1.17 million grant to the University of Oxford to support a…
Savara Presents New Exercise Capacity Data from IMPALA-2 Phase 3 Trial of Molgramostim in aPAP at ATS 2026 International Conference Savara a clinical-stage biopharmaceutical company focused on developing therapies for…
Vir Biotechnology to Showcase Full 96-Week Phase 2 SOLSTICE Hepatitis Delta Trial Results at European Association for the Study of the Liver Congress 2026 Vir Biotechnology announced that new clinical…
CareTrust REIT, Inc. Prices Enlarged Public Common Stock Offering CareTrust REIT, Inc. has announced the pricing of an enlarged underwritten public offering of its common stock, a move expected to…
NEJM Publishes Shionogi Phase 3 SCORPIO-PEP Study Showing Ensitrelvir Significantly Reduces COVID-19 Risk After Exposure Shionogi & Co., Ltd. announced that results from its global Phase 3 clinical trial, SCORPIO-PEP,…
Health Executives Partner to Create Pioneering Women’s Health AI Initiative The women’s health industry is entering a transformative new era with the launch of the Women’s Health AI Consortium, a…